Trademark: 97392449
Status Date
Wednesday, November 29, 2023
Filing Date
Tuesday, May 3, 2022
Published for Opposition
Tuesday, April 4, 2023
5 pharmaceutical and biological preparations utilizing aCT1 peptide to restore Connexin43 protein junction integrity in cells, namely, ophthalmic eye drops useful in treating corneal injuries or ocular injury due to chemical agents, dermatological topical formulations useful in treating cutaneous radiation injuries, cutaneous scarring, and thermal burns, and inhalation solutions useful in treating acute lung injuries
42 biopharmaceutical research and development services utilizing aCT1 peptide to restore Connexin43 protein junction integrity in cells, in the fields of dermatology, ophthalmology, and pulmonology
Nov 30, 2023
Notice Of Approval Of Extension Request E-Mailed
Nov 29, 2023
Sou Extension 1 Granted
Nov 29, 2023
Sou Extension 1 Filed
Nov 29, 2023
Sou Teas Extension Received
May 30, 2023
Noa E-Mailed - Sou Required From Applicant
Apr 4, 2023
Official Gazette Publication Confirmation E-Mailed
Apr 4, 2023
Published For Opposition
Mar 15, 2023
Notification Of Notice Of Publication E-Mailed
Mar 1, 2023
Approved For Pub - Principal Register
Feb 22, 2023
Assigned To Examiner
May 6, 2022
New Application Office Supplied Data Entered
May 6, 2022
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24
